SI-BONE, Inc.
Financials
Valuation Metrics
SI-BONE, Inc.'s Market Cap is $898M. At end of 2025 it was $858M. Ranked #2438 of 3,114 in US market (top 78%), #995 of 1,469 on NASDAQ (top 68%), #158 of 203 in Health Care Equipment & Services (top 78%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $898M | US#2,438/3,114 Sec#158/203 |
| Revenue | $214M | US#2,538/3,114 Sec#168/203 |
| Net Income | $-15M | US—/3,114 Sec—/203 |
| Total Assets | $249M | US#2,948/3,114 Sec#181/203 |
| Net Assets | $182M | US#2,702/3,114 Sec#163/203 |
| Employees | 376 | US#2,345/3,114 Sec#163/203 |
| Value | ||
| P/B | 4.92x | US#2,266/3,114 Sec#137/203 |
| P/S | 4.20x | US#2,194/3,114 Sec#144/203 |
| FCF Yield | -0.49% | US—/3,114 Sec—/203 |
| Profitability | ||
| ROE | -8.03% | US#2,323/3,114 Sec#129/203 |
| ROA | -5.88% | US#2,557/3,114 Sec#143/203 |
| Op. Margin | -8.31% | US#2,503/3,114 Sec#152/203 |
| Revenue Growth | 15.30% | US#887/3,114 Sec#61/203 |
| Financial Health | ||
| Debt Ratio | 36.42% | US#418/3,114 Sec#45/203 |
| Total Debt | $7M | US#2,869/3,114 Sec#191/203 |
| FCF | $-4M | US#2,343/3,114 Sec#148/203 |
| Cash | $33M | US#2,728/3,114 Sec#177/203 |
| Current Ratio | 9.15x | US#282/3,114 Sec#14/203 |
| Performance | ||
| 1Y Return | 36.48% | US#628/3,114 Sec#53/203 |
| 1M Return | 11.95% | US#262/3,114 Sec#28/203 |
| From 52W High | -11.81% | US#177/3,114 Sec#16/203 |
| 1Y MDD | -45.75% | US#2,203/3,114 Sec#138/203 |
| Trading | ||
| Volume | 1,237,809 shares | US#2,069/3,114 Sec#139/203 |
| Trading Value | $26M | US#2,240/3,114 Sec#150/203 |
| Per Share | ||
| EPS | $-0.33 | US—/3,114 Sec—/203 |
| BPS | $4.11 | US#2,343/3,114 Sec#148/203 |
Company Info
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.